James E. Wagner Cultivation Corporation (JWCAF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
James E. Wagner Cultivation Corporation (JWCAF) trades at $0.00 with AI Score 60/100 (Grade B+). James E. Wagner Cultivation Corporation cultivates and sells medical cannabis in Canada. Market cap: $10,942, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for JWCAF: JWCAF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates JWCAF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
JWCAF: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →James E. Wagner Cultivation Corporation (JWCAF) Healthcare & Pipeline Overview
James E. Wagner Cultivation Corporation focuses on the Canadian medical cannabis market, utilizing its GrowthSTORM aeroponic platform for consistent production. The company faces challenges in a competitive landscape with negative profit and gross margins, requiring strategic adaptation for long-term viability.
What Is the Investment Thesis for JWCAF?
Investing in James E. Wagner Cultivation Corporation (JWCAF) presents a high-risk, high-reward scenario. The company's negative profit margin of -327.9% and gross margin of -89.2% indicate significant financial challenges. JWCAF's success hinges on its ability to improve operational efficiency, reduce costs, and increase revenue. The potential legalization of recreational cannabis in Canada could provide a substantial growth catalyst, but JWCAF must navigate intense competition and regulatory hurdles. The company's proprietary GrowthSTORM aeroponic platform offers a potential competitive advantage, but its long-term viability depends on successful execution and market acceptance. Investors should closely monitor JWCAF's financial performance, regulatory developments, and competitive positioning before making any investment decisions. The company's beta of 0.63 suggests lower volatility compared to the overall market, but its financial instability warrants caution.
Based on FMP financials and quantitative analysis
JWCAF Key Highlights
- Market Cap of 11K indicates a micro-cap company with limited resources.
- P/E Ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -327.9% signals significant operational inefficiencies and potential financial distress.
- Gross Margin of -89.2% demonstrates that the cost of goods sold exceeds revenue, posing a major challenge.
- Beta of 0.63 suggests lower volatility compared to the market, but financial instability remains a concern.
Who Are JWCAF's Competitors?
JWCAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| NPNKF Nippon Shinyaku Co., Ltd. | $32.75 | +4.30% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JWCAF's Key Strengths?
- Proprietary GrowthSTORM aeroponic platform.
- Focus on clean and consistent cannabis production.
- Established presence in the Canadian medical cannabis market.
- Expertise in controlled environment agriculture.
What Are JWCAF's Weaknesses?
- Negative profit and gross margins.
- Limited financial resources.
- High dependence on the Canadian market.
- Small market capitalization.
What Could Drive JWCAF Stock Higher?
- Potential legalization of recreational cannabis in Canada, which could expand the market for JWCAF's products.
- Optimization of the GrowthSTORM aeroponic platform to improve yields and reduce costs.
- Expansion of product offerings to include edibles, concentrates, and other cannabis-derived products.
What Are the Key Risks for JWCAF?
- Financial-distress signal — its Altman Z-Score of -1.22 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-45.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the Canadian cannabis market, which could erode JWCAF's market share.
- Stringent regulations and changing regulatory landscape, which could increase compliance costs.
- Fluctuations in cannabis prices, which could impact JWCAF's revenue and profitability.
- Potential for oversupply in the market, which could drive down prices and reduce margins.
- Negative profit and gross margins, which raise concerns about JWCAF's financial sustainability.
What Are the Growth Opportunities for JWCAF?
- Expansion of Product Offerings: JWCAF can expand its product offerings beyond medical cannabis to include a wider range of cannabis-derived products, such as edibles, concentrates, and topicals. This diversification can attract new customers and increase revenue streams. The market for cannabis-infused products is growing rapidly, with projections estimating a multi-billion dollar market in the coming years. Timeline: Within the next 2-3 years, JWCAF can develop and launch new product lines, leveraging its existing cultivation infrastructure and distribution channels.
- Strategic Partnerships: JWCAF can form strategic partnerships with other companies in the cannabis industry, such as distributors, retailers, and technology providers. These partnerships can provide access to new markets, technologies, and expertise. Collaborations can enhance JWCAF's competitive position and accelerate growth. The cannabis industry is increasingly characterized by strategic alliances and collaborations. Timeline: Ongoing, with potential partnerships to be established within the next year.
- International Expansion: JWCAF can explore opportunities to expand its operations into international markets, such as Europe and Latin America, where medical cannabis is legal or becoming legal. International expansion can diversify revenue streams and reduce reliance on the Canadian market. The global cannabis market is expected to grow significantly in the coming years. Timeline: Within the next 3-5 years, JWCAF can conduct market research and establish partnerships to enter select international markets.
- Focus on Research and Development: JWCAF can invest in research and development to develop new cannabis strains, cultivation techniques, and product formulations. This can lead to the development of innovative products with unique therapeutic benefits. Innovation can differentiate JWCAF from its competitors and attract customers seeking high-quality, effective cannabis products. Timeline: Ongoing, with continuous investment in R&D to drive product innovation.
- Leveraging the GrowthSTORM Platform: JWCAF should maximize the potential of its proprietary GrowthSTORM aeroponic platform. By optimizing the platform for different cannabis strains and environmental conditions, JWCAF can improve yields, reduce costs, and enhance product quality. The GrowthSTORM platform can provide a competitive advantage in terms of consistency and efficiency. Timeline: Ongoing, with continuous optimization of the GrowthSTORM platform to improve operational performance.
What Opportunities Does JWCAF Have?
- Expansion of product offerings to include edibles and concentrates.
- Strategic partnerships with distributors and retailers.
- International expansion into new markets.
- Investment in research and development to develop innovative products.
What Threats Does JWCAF Face?
- Intense competition in the Canadian cannabis market.
- Stringent regulations and changing regulatory landscape.
- Fluctuations in cannabis prices.
- Potential for oversupply in the market.
What Are JWCAF's Competitive Advantages?
- Proprietary aeroponic platform (GrowthSTORM) for consistent cannabis production.
- Focus on clean and high-quality medical cannabis.
- Established presence in the Canadian medical cannabis market.
- Expertise in controlled environment agriculture.
What Does JWCAF Do?
James E. Wagner Cultivation Corporation (JWCAF), founded in 2007 and headquartered in Kitchener, Canada, operates through its subsidiary, James E. Wagner Cultivation Ltd., focusing on the cultivation and sale of medical cannabis within Canada. The company distinguishes itself through its proprietary aeroponic platform known as GrowthSTORM, designed to ensure the consistent production of clean cannabis. This technology underscores JWCAF's commitment to quality and consistency in a highly regulated market. JWCAF's business model centers around cultivating and distributing medical cannabis to patients, leveraging its controlled environment production system to meet stringent quality standards. The company's focus remains on the Canadian market, where it navigates the evolving regulatory landscape and increasing competition. JWCAF's strategy involves optimizing its cultivation techniques and expanding its product offerings to cater to diverse patient needs within the medical cannabis sector. The company aims to establish a strong brand presence and build lasting relationships with healthcare professionals and patients alike.
What Products and Services Does JWCAF Offer?
- Cultivates medical cannabis in Canada.
- Utilizes a proprietary aeroponic platform called GrowthSTORM.
- Focuses on producing clean and consistent cannabis.
- Sells medical cannabis to patients.
- Operates through its subsidiary, James E. Wagner Cultivation Ltd.
- Aims to meet stringent quality standards in cannabis production.
How Does JWCAF Make Money?
- Cultivates medical cannabis using its GrowthSTORM platform.
- Sells cannabis products directly to patients or through distributors.
- Generates revenue from the sale of medical cannabis.
- Focuses on the Canadian medical cannabis market.
What Industry Does JWCAF Operate In?
James E. Wagner Cultivation Corporation operates in the rapidly evolving Canadian cannabis industry, which is characterized by increasing competition and regulatory changes. The market is driven by growing acceptance of cannabis for medical and recreational use. JWCAF competes with larger, more established players like ANTCF (Aurora Cannabis Inc.) and BHNGF (Bhang Inc.), as well as smaller specialty producers. The industry is subject to stringent regulations regarding cultivation, distribution, and marketing, which can impact profitability. Companies must adapt to changing consumer preferences and invest in research and development to stay competitive. The Canadian cannabis market is expected to continue growing, but success depends on efficient operations, strong branding, and regulatory compliance.
Who Are JWCAF's Key Customers?
- Patients requiring medical cannabis for various conditions.
- Healthcare professionals prescribing medical cannabis.
- Distributors of medical cannabis products.
- Pharmacies dispensing medical cannabis.
How James E. Wagner Cultivation Corporation Is Valued
James E. Wagner Cultivation Corporation carries a market capitalization of 11K, placing it in the micro-cap category. Relative to its peer group, JWCAF's quantitative score of 60/100 is roughly in line with the peer average of 66/100.
Company Profile
James E. Wagner Cultivation Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Kitchener, CA. The company is led by CEO Nathaniel Woodworth. JWCAF has traded publicly since 2018.
ROE -45%Key Financial Metrics
Return on equity for James E. Wagner Cultivation Corporation stands at -45.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -31.9%, showing how much profit it generates from its asset base. A current ratio of 1.48 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
James E. Wagner Cultivation Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.22 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project James E. Wagner Cultivation Corporation revenue of about $2.2M for fiscal 2026, with EPS near $-0.08.
JWCAF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider activity suggests confidence in the company's future, hinting at potential positive developments not yet reflected in the market. The community has shown optimism regarding the company's strategic shift towards higher-margin products. Market perception indicates a growing acceptance of craft cannabis, potentially benefiting JWCAF's brand positioning. Bullish community views highlight the company's strong cultivation practices and commitment to quality, which could drive future demand.
Bear Case
- Bearish community views express concern over the company's ability to compete with larger, more established players in the cannabis industry. Market perception suggests increasing regulatory scrutiny, potentially impacting JWCAF's operational costs and expansion plans. Community sentiment reflects uncertainty about the company's long-term financial stability amidst ongoing industry consolidation. Recent insider activity, if any selling, could signal a lack of confidence in the short-term outlook, similar to concerns seen with other smaller cannabis firms facing market pressures.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
JWCAF Latest News
-
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
benzinga · Dec 18, 2025
-
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
benzinga · Dec 17, 2025
-
Hess Midstream Signs $100M Repurchase That Includes Class B Units Of Hess Midstream Operations From chevron Affiliate And Hess Midstream's Class A Shares From Public
benzinga · Aug 5, 2025
-
'GOP-Led Congressional Panel Demands Investigation On Biden's Marijuana Rescheduling Process, Citing 'Deviations' And 'Mental Health Hazards'' -Marijuana Moment Report
benzinga · Jun 10, 2025
JWCAF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JWCAF.
Price Targets
Wall Street price target analysis for JWCAF.
JWCAF MoonshotScore
What does this score mean?
The MoonshotScore rates JWCAF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
Hess Midstream Signs $100M Repurchase That Includes Class B Units Of Hess Midstream Operations From chevron Affiliate And Hess Midstream's Class A Shares From Public
'GOP-Led Congressional Panel Demands Investigation On Biden's Marijuana Rescheduling Process, Citing 'Deviations' And 'Mental Health Hazards'' -Marijuana Moment Report
Leadership: Nathaniel Woodworth
CEO
Nathaniel Woodworth serves as the CEO of James E. Wagner Cultivation Corporation. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive background on Mr. Woodworth's professional experience and qualifications.
Track Record: Due to the limited information available, it is not possible to assess Nathaniel Woodworth's track record at James E. Wagner Cultivation Corporation. Key achievements, strategic decisions, and company milestones under his leadership are currently unknown.
JWCAF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that James E. Wagner Cultivation Corporation may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information, price volatility, and illiquidity. These companies may not be current in their reporting obligations, making it difficult for investors to assess their financial health and prospects.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The unknown disclosure status raises concerns about the availability of reliable financial information.
- Low Liquidity: The OTC Other tier status suggests limited trading volume and wide bid-ask spreads.
- Regulatory Uncertainty: OTC-traded companies may be subject to less regulatory oversight than exchange-listed companies.
- Potential for Fraud: The lack of scrutiny on the OTC market increases the risk of fraudulent or manipulative activities.
- Going Concern Risk: The company's negative profit and gross margins raise concerns about its ability to continue operating.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's competitive position and market share.
- Evaluate the company's business model and revenue streams.
- Review the company's legal and regulatory compliance.
- Check for any outstanding legal or regulatory issues.
- Consult with a qualified financial advisor.
- Established presence in the Canadian medical cannabis market.
- Proprietary GrowthSTORM aeroponic platform.
- Focus on clean and consistent cannabis production.
- Operations through a subsidiary, James E. Wagner Cultivation Ltd.
What Investors Ask About James E. Wagner Cultivation Corporation (JWCAF) — Healthcare
What does James E. Wagner Cultivation Corporation do?
James E. Wagner Cultivation Corporation, through its subsidiary James E. Wagner Cultivation Ltd., cultivates and sells medical cannabis in Canada. The company's core business revolves around producing high-quality cannabis using its proprietary GrowthSTORM aeroponic platform. This platform allows for consistent and controlled cultivation, ensuring the production of clean and reliable medical cannabis products. JWCAF focuses on serving the Canadian medical cannabis market, catering to patients with various medical conditions who require access to regulated and quality-controlled cannabis products. The company aims to establish itself as a trusted provider of medical cannabis through its commitment to quality, consistency, and innovation in cultivation techniques.
What do analysts say about JWCAF stock?
Due to the limited information available and the company's OTC Other tier status, analyst coverage of JWCAF stock is likely minimal or non-existent. Key valuation metrics such as price targets and buy/sell recommendations are unlikely to be available. Investors should rely on their own independent research and due diligence to assess the company's prospects and risks. Factors to consider include JWCAF's financial performance, competitive positioning, regulatory environment, and growth opportunities. The company's negative profit and gross margins warrant caution, and investors should carefully evaluate its ability to improve its financial performance and achieve profitability. The potential legalization of recreational cannabis in Canada could provide a growth catalyst, but JWCAF must navigate intense competition and regulatory hurdles.
What are the main risks for JWCAF?
James E. Wagner Cultivation Corporation faces several significant risks, primarily stemming from its financial instability and the competitive landscape of the Canadian cannabis market. The company's negative profit and gross margins indicate operational inefficiencies and raise concerns about its long-term viability. Intense competition from larger, more established cannabis companies poses a threat to JWCAF's market share and pricing power. Stringent regulations and changing regulatory requirements can increase compliance costs and limit the company's operational flexibility. Fluctuations in cannabis prices and the potential for oversupply in the market can negatively impact JWCAF's revenue and profitability. The company's OTC Other tier status and unknown disclosure level also increase the risk for investors due to limited information and regulatory oversight.
What are the key factors to evaluate for JWCAF?
James E. Wagner Cultivation Corporation (JWCAF) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does JWCAF data refresh on this page?
JWCAF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven JWCAF's recent stock price performance?
James E. Wagner Cultivation Corporation (JWCAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary GrowthSTORM aeroponic platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider JWCAF overvalued or undervalued right now?
Valuing James E. Wagner Cultivation Corporation (JWCAF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying JWCAF?
Before investing in James E. Wagner Cultivation Corporation (JWCAF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC status and lack of analyst coverage.
- Financial data is based on available information and may not be fully comprehensive.
- The analysis is based on the assumption that the provided data is accurate and reliable.